The frequencies of VTE did not differ significantly based on INR range or receipt of VTE prophylaxis. Of the 190 patients in the study, 17 (9%) received pharmacologic VTE prophylaxis and 31 (16% ...

In an investigation of the risk factors for VTE in patients with cervical cancer, a research team developed an assay kit for TAT and then conducted a retrospective analysis on 177 patients with ...

Once-daily venous thromboembolism (VTE) prophylaxis with 10 mg of rivaroxaban for either 7 or 28 days after bariatric surgery was found to be effective and safe.

Dr. Nigel Key and Dr. Anna Falanga join us for a conversation on the updated ASCO VTE prophylaxis and treatment in patients with cancer guideline. They discuss recent evidence assessing apixaban for ...

Given the dearth of randomized controlled trials available with regard to VTE in patients with multiple myeloma, a simplified, expert-based approach to prophylaxis at various stages of MM, treated ...

Another factor that may have been at play, as noted by Spyropoulos, was that the trial design did not allow for ascertainment of continuous adherence to the prescribed prophylaxis. IMPROVE-DD VTE ...

Among 126,104 patients from the 2016 Nationwide Readmissions Database, readmission rates for VTE were 0.6%, 1.1%, and 1.7% at 30-, 90-, and 180-days after cancer surgery, respectively, Syed Nabeel ...

Rationale VTE risk assessments are carried out for most people admitted to hospital, but the results are not always acted on promptly, meaning that pharmacological prophylaxis can be delayed and the ...

Rationale A significant number of people are discharged after hospital treatment for trauma or orthopaedic surgery with temporary lower limb immobilisation. These people may have an increased risk of ...

A new set of guidelines, developed by AATS and ESTS (European Society for Thoracic Surgery) presented today at the AATS 101st Annual Meeting, recommends a 30-day course of Venous Thromboembolism ...

Two recent clinical trials have demonstrated that direct oral anticoagulants (DOACs) are effective as venous thromboembolism (VTE) prophylaxis in patients with moderate-to-high risk ambulatory cancer ...